A study presented at the CHEST Annual Meeting found that elexacaftor/tezacaftor/ivacaftor (ETI) was equally effective in improving lung function, BMI, and other factors in patients with cystic fibrosis, regardless of prior exposure to cystic fibrosis transmembrane conductance regulator modulators. Researchers observed significant improvements in various factors, including FEV1, BMI, and positivity for specific infections in patients treated with ETI for one year. The study also showed improvements in chronic rhinosinusitis and a reduction in the use of certain medications. Overall, the study suggests that previous exposure to CFTR modulators does not limit the benefits of ETI therapy.
Source link
Cystic fibrosis triple therapy outcomes improve regardless of prior modulators
